Meeting
2021 Gastrointestinal Cancers Symposium
Polymorphisms of pluripotency transcription factors for predicting cetuximab efficacy in metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
Authors
Hiroyuki Arai
Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA
Hiroyuki Arai , Joshua Millstein , Fotios Loupakis , Sebastian Stintzing , Jingyuan Wang , Francesca Battaglin , Natsuko Kawanishi , Shivani Soni , Zhang Wu , Chiara Cremolini , Volker Heinemann , Alfredo Falcone , Heinz-Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 98)
DOI
10.1200/JCO.2021.39.3_suppl.98
Abstract #
98
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The role of germline polymorphisms in genes involved in the antioxidant system to predict the efficacy of cetuximab for patients with metastatic colorectal cancer (mCRC) enrolled in FIRE-3 trial.
First Author: Hiroyuki Arai
Poster
2021 ASCO Annual Meeting
Germline polymorphisms in genes maintaining replication fork to predict the efficacy of oxaliplatin and irinotecan in metastatic colorectal cancer (mCRC) patients enrolled in MAVERICC trial.
First Author: Hiroyuki Arai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Effectiveness of biologic agents among Hispanics in the US with metastatic colorectal cancer.
First Author: Riya Jayesh Patel
Poster
2022 ASCO Annual Meeting
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
First Author: Hiroyuki Arai